NLRP3 and Parkinson disease: Given that there is a strong link between NLRP3, NRF2, and mitochondrial dysfunction, agents targeting either NLRP3 and/or NRF2 may have additive beneficial effects of anti-inflammation and enhancing mitochondrial biogenesis in PD (Khot et al., 2022; Han and Le, 2023; Rajan et al., 2023).